Key Highlights

• 43% First-Cycle Complete Remission Rate: The Annamycin plus HiDAC combination achieved 43% and 36% first-cycle complete remission rates versus 12% in the HiDAC monotherapy control arm.

• Composite CR Rates Reach 57%: Composite complete remission rates of up to 57% represent a clinically meaningful improvement over the control arm.

• Strong Validation for Ongoing Enrollment: The data supports continued enrollment and final dose optimization in the ongoing MIRACLE trial.

Moleculin Biotech (NASDAQ: MBRX) released encouraging interim results from its Phase 2/3 MIRACLE trial evaluating the combination of Annamycin and High-Dose Cytarabine (HiDAC) in patients with relapsed or refractory acute myeloid leukemia, demonstrating superior efficacy over HiDAC monotherapy across all primary efficacy measures.

The data revealed first-cycle complete remission rates of 43% and 36% across different dose cohorts of the Annamycin plus HiDAC combination, compared to just 12% in the HiDAC monotherapy control arm, representing a three to four-fold improvement in the proportion of patients achieving the most clinically meaningful early response.

Composite complete remission rates, which capture patients achieving complete remission with or without full count recovery, reached as high as 57% in the combination arm, providing additional evidence of the treatment's clinical activity in a patient population that historically faces extremely poor outcomes with standard salvage chemotherapy.

Relapsed and refractory acute myeloid leukemia represents one of the most difficult-to-treat cancer subsets in all of oncology. Most patients who relapse after initial induction chemotherapy or who fail to respond to frontline treatment have very limited options, with response rates to standard salvage regimens typically in the range of 10% to 30%, making the MIRACLE trial's combination arm results clinically noteworthy.

The interim data provides strong validation for continued enrollment in the ongoing trial and will inform the final dose optimization strategy for Annamycin within the combination regimen. Moleculin Biotech (NASDAQ: MBRX) will need to complete enrollment and generate final data to support a potential regulatory submission, though the interim results represent a meaningfully positive signal for the program's development trajectory.

()